The main objective of the clinical development programme for BDP Modulite@, a new non-extra fine formulation of beclometasone dipropionate (BDP) in hydrofluoroalkane (HFA), has been to demonstrate therapeutic equivalence compared with standard BDP chlorofluorocarbon (CFC) products at the recommended posology (delivered dose and patient population).A total of I I58 asthmatic patients were included in five clinical studies and 658 patients were treated with BDP Modulite@'. Four studies were undertaken in mild or moderate-to-severe asthmatic adults, while one study was carried out in children.The duration of treatment was I2 weeks in three studies and 6 weeks in the other two studies. A range of doses of BDP Modulite@ from 200 pg bid up to I500 pg bid was evaluated against CFC comparators.
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